New Advances in Cardiac & Vascular Research
Investigators at NYU Langone Health have made fundamental strides in cardiovascular research over the last year.
New AI Tool Makes Speedy Gene Editing Possible
NYU Langone’s artificial intelligence program quickly designs customizable proteins to treat diseases by turning genes on and off.
New Alzheimer’s Drug Is First of Its Kind to Be FDA Approved
NYU Langone neurologist Dr. Joel Salinas discusses the FDA approval of Aduhelm (aducanumab) to treat early Alzheimer’s disease.
New Alzheimer’s Research Targets Amyloid Beta Proteins
NYU Langone Alzheimer’s and dementia researchers present latest findings at 2016 Alzheimer’s Association International Conference.
New Ambulatory Care Center Opens in Midtown Manhattan
NYU Langone Ambulatory Care Center East 41st Street, opening April 9, 2018, is one of NYU Langone’s largest ambulatory facilities.
New Anti-Aging Properties Found in Old Diabetes Drugs
NYU Langone researchers find that a type of medication used to increase insulin sensitivity can prevent or delay many age-related pathologies.
New Antibodies Show Potential Against Neurological Diseases
NYU Langone study finds experimental antibodies target a structural feature shared by proteins linked to several neurological conditions.
New Approach Enhances Patient Success in Managing Diabetes
Dr. Lauren H. Golden, at NYU Langone’s Center for Diabetes and Metabolic Health, focuses on enhancing patient success in diabetes management.
New Approach for Treating Childhood Leukemia
New research from NYU Langone suggests that targeting tumor cells’ microenvironment could lead to new treatments for childhood leukemia.
New Approach Promises to Revolutionize MRI Scanner Design
NYU Langone researchers harness imperfections that typically compromise MRI exams to achieve superior images.